Suchergebnisse - "Bender, David P"

PubPharm (45)

1

NRG-GY012 : Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

enthalten in: Cancer | 2024

von Rimel, B. | Enserro, D. | Bender, D. | +10

2

Microbial Communities in Gynecological Cancers and Their Association with Tumor Somatic Variation

enthalten in: Cancers | 2023

von Gonzalez-Bosquet, J. | McDonald, M. | Bender, D. | +4

3

Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer : A Gynecologic Oncology Group 0212:NRG Oncology Study

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Copeland, L. | Brady, M. | Burger, R. | +18

CommentIn: Ann Transl Med. 2023 Mar 31;11(6):275. - PMID 37082657

4

Using Genomic Variation to Distinguish Ovarian High-Grade Serous Carcinoma from Benign Fallopian Tubes

enthalten in: International journal of molecular sciences | 2022

von Gonzalez-Bosquet, J. | Cardillo, N. | Reyes, H. | +5

5

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high-grade serous ovarian cancer

enthalten in: Acta obstetricia et gynecologica Scandinavica | 2022

von Cardillo, N. | Devor, E. | Calma, C. | +5

6

Integrated Clinical and Genomic Models to Predict Optimal Cytoreduction in High-Grade Serous Ovarian Cancer

enthalten in: Cancers | 2022

von Cardillo, N. | Devor, E. | Pedra Nobre, S. | +6

7

Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004) : A Randomized, Open-Label, Phase III Trial

enthalten in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2022

von Liu, J. | Brady, M. | Matulonis, U. | +18

8

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer

enthalten in: Acta Obstetricia et Gynecologica Scandinavica | 2022

von Cardillo, N. | Devor, E. | Calma, C. | +5

9

The Synthetic Curcumin Analog HO-3867 Rescues Suppression of PLAC1 Expression in Ovarian Cancer Cells

enthalten in: Pharmaceuticals (Basel, Switzerland) | 2021

von Devor, E. | Schickling, B. | Lapierre, J. | +3

10

Creation and validation of models to predict response to primary treatment in serous ovarian cancer

enthalten in: Scientific reports | 2021

von Gonzalez Bosquet, J. | Devor, E. | Newtson, A. | +7

1
2
3
4
5
Nächster »
[5]